Positron emission tomography (PET) study with (11C)flumazenil to determine central GABAA receptor occupancy of AZD7325 - PET
Study identifier:D1140C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open label positron emission tomography (PET) study with (11C)flumazenil to determine central GABAA receptor occupancy of AZD7325 after oral administration to healthy volunteers
Medical condition
Anxiety
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD7325, Radioligand (11C) flumazenil
Sex
Male
Actual Enrollment
4
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Feb 2008
Primary Completion Date: 01 Jul 2008
Study Completion Date: 01 Jul 2008
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD7325 Single dose of oral solution or capsule. 3 times per subject. Drug: Radioligand (11C) flumazenil Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325) |
Contacts
Investigators
Principal Investigator
Bo Fransson
AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden
